Polpharma European CDMO Partner & API Manufacturer since 1951 Polpharma European CDMO Partner & API Manufacturer since 1951

X

Digital content for Revive Therapeutics

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Revive Therapeutics
Canada Flag
Country
Country
Canada
Address
Address
82 Richmond Street East Toronto, Ontario M5C 1P1
Telephone
Telephone
905-605-5535
Linkedin
Linkedin
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

https://www.globenewswire.com/news-release/2024/04/23/2867498/0/en/Revive-Therapeutics-Announces-Type-C-Meeting-Request-Granted-by-FDA-for-Clinical-Study-of-Bucillamine-to-Treat-Long-COVID.html

GLOBENEWSWIRE
23 Apr 2024

https://www.globenewswire.com/news-release/2024/04/18/2865256/0/en/Revive-Therapeutics-Announces-FDA-Acceptance-of-Meeting-Request-for-Long-COVID-Diagnostic-Product.html

GLOBENEWSWIRE
18 Apr 2024

https://www.globenewswire.com/news-release/2024/04/02/2855836/0/en/Revive-Therapeutics-Provides-Update-on-Psilocybin-Clinical-Study-for-Methamphetamine-Use-Disorder.html

GLOBENEWSWIRE
02 Apr 2024

https://www.globenewswire.com/news-release/2024/03/27/2853251/0/en/Revive-Therapeutics-Submits-Type-C-Meeting-Request-Package-to-FDA-for-Clinical-Study-of-Bucillamine-to-Treat-Long-COVID.html

GLOBENEWSWIRE
27 Mar 2024

https://www.globenewswire.com/news-release/2024/03/19/2848420/0/en/Revive-Therapeutics-To-Submit-Type-C-Meeting-Request-with-FDA-for-Bucillamine-to-Treat-Long-COVID.html

GLOBENEWSWIRE
19 Mar 2024

https://www.globenewswire.com//news-release/2024/03/12/2844382/0/en/Revive-Therapeutics-Provides-Corporate-Update.html

GLOBENEWSWIRE
12 Mar 2024

https://www.globenewswire.com//news-release/2024/02/26/2835487/0/en/Revive-Therapeutics-Ltd-Announces-Closing-of-the-Second-and-Final-Tranche-of-Its-Private-Placement-for-Gross-Proceeds-of-1-187-110.html

GLOBENEWSWIRE
26 Feb 2024

https://www.globenewswire.com//news-release/2024/02/01/2821891/0/en/Revive-Therapeutics-Explores-the-Use-of-Bucillamine-for-Long-COVID.html

GLOBENEWSWIRE
01 Feb 2024

https://www.globenewswire.com/news-release/2024/01/31/2821606/0/en/Revive-Therapeutics-Ltd-Announces-Closing-of-the-First-Tranche-of-Its-Private-Placement-for-Gross-Proceeds-of-913-500.html

GLOBENEWSWIRE
31 Jan 2024

https://www.globenewswire.com//news-release/2024/01/24/2816162/0/en/Revive-Therapeutics-Ltd-Announces-Offering-of-Up-to-3-Million.html

GLOBENEWSWIRE
24 Jan 2024
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY